Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoSem4Chemsex: Semaglutide plus counselling for chemsex-related drug craving
2025-524177-16-00Phase 2Authorised
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaglutide in substance use disorder (SUD) and alcohol use disorder (AUD), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: Craving for chemsex-associated drugs (Penn Craving Score). Planned start Feb 2026; status: authorised.
02
Drugs
03
Conditions
substance use disorder (SUD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2025-524177-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524177-16-00.